CL2019003915A1 - Métodos de purificación de columna de vector aav. - Google Patents
Métodos de purificación de columna de vector aav.Info
- Publication number
- CL2019003915A1 CL2019003915A1 CL2019003915A CL2019003915A CL2019003915A1 CL 2019003915 A1 CL2019003915 A1 CL 2019003915A1 CL 2019003915 A CL2019003915 A CL 2019003915A CL 2019003915 A CL2019003915 A CL 2019003915A CL 2019003915 A1 CL2019003915 A1 CL 2019003915A1
- Authority
- CL
- Chile
- Prior art keywords
- chromatography
- purification methods
- column purification
- affinity
- aav
- Prior art date
Links
- 238000000746 purification Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 4
- 238000001042 affinity chromatography Methods 0.000 abstract 2
- 238000004440 column chromatography Methods 0.000 abstract 2
- 238000005571 anion exchange chromatography Methods 0.000 abstract 1
- 238000005277 cation exchange chromatography Methods 0.000 abstract 1
- 238000002270 exclusion chromatography Methods 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/362—Cation-exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
- B01D15/361—Ion-exchange
- B01D15/363—Anion-exchange
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527633P | 2017-06-30 | 2017-06-30 | |
| US201762531744P | 2017-07-12 | 2017-07-12 | |
| US201762567905P | 2017-10-04 | 2017-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003915A1 true CL2019003915A1 (es) | 2020-06-19 |
Family
ID=64742749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003915A CL2019003915A1 (es) | 2017-06-30 | 2019-12-30 | Métodos de purificación de columna de vector aav. |
Country Status (16)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61387B2 (sr) | 2013-02-15 | 2024-06-28 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| ES2965341T3 (es) | 2019-04-11 | 2024-04-12 | Regenxbio Inc | Métodos de cromatografía de exclusión por tamaño para la caracterización de composiciones de virus adenoasociados recombinantes |
| JP7803014B2 (ja) | 2019-09-30 | 2026-01-21 | バイオベラティブ セラピューティクス インコーポレイテッド | レンチウイルスベクター製剤 |
| AU2021262609A1 (en) | 2020-05-01 | 2022-12-22 | Kashiv Biosciences, Llc | An improved process of purification of protein |
| EP3919613B1 (en) * | 2020-06-05 | 2024-08-07 | Sartorius BIA Separations d.o.o. | Enhanced purification of adeno-associated virus to more effectively remove contaminating dna |
| JP2023537565A (ja) * | 2020-06-24 | 2023-09-04 | バイオベラティブ セラピューティクス インコーポレイテッド | タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法 |
| US20220033782A1 (en) * | 2020-07-29 | 2022-02-03 | Pall Corporation | Adenovirus-associated viruses separation method |
| US20220154223A1 (en) | 2020-10-15 | 2022-05-19 | Hoffmann-La Roche Inc. | Nucleic acid constructs for simultaneous gene activation |
| WO2022079083A1 (en) | 2020-10-15 | 2022-04-21 | F. Hoffmann-La Roche Ag | Nucleic acid constructs for va rna transcription |
| JP7767029B2 (ja) * | 2021-05-28 | 2025-11-11 | ダイセン・メンブレン・システムズ株式会社 | 細胞外小胞の分離精製方法 |
| JP7716233B2 (ja) * | 2021-05-28 | 2025-07-31 | ダイセン・メンブレン・システムズ株式会社 | 微小有用物質の分離精製方法と分離精製装置 |
| BR112023025999A2 (pt) * | 2021-06-11 | 2024-02-27 | Spark Therapeutics Inc | Métodos de purificação de coluna de vetor de aav |
| WO2023023541A1 (en) * | 2021-08-17 | 2023-02-23 | Ultragenyx Pharmaceutical Inc. | Anion-exchange chromatography methods for purification of recombinant adeno-associated viruses |
| EP4408857A4 (en) * | 2021-09-28 | 2025-11-05 | Kashiv Biosciences Llc | IMPROVED PROCESS FOR PURIFICATION OF FUSION PROTEIN |
| CN114250222A (zh) * | 2021-12-08 | 2022-03-29 | 苏州博腾生物制药有限公司 | 一种从动物组织中提取aav dna的方法 |
| GB202117844D0 (en) * | 2021-12-09 | 2022-01-26 | Oxford Biomedica Ltd | Purification method |
| JP7898711B2 (ja) * | 2022-03-24 | 2026-08-03 | 国立大学法人 東京大学 | ウイルスの精製方法 |
| EP4508241A1 (en) | 2022-04-13 | 2025-02-19 | F. Hoffmann-La Roche AG | Method for determining aav genomes |
| EP4529614A1 (en) | 2022-05-23 | 2025-04-02 | F. Hoffmann-La Roche AG | Raman-based method for the differentiation of aav particle serotype and aav particle loading status |
| JP2025519228A (ja) | 2022-06-03 | 2025-06-24 | エフ． ホフマン－ラ ロシュ アーゲー | 組換えａａｖ粒子を生成するための方法 |
| WO2024013239A1 (en) | 2022-07-14 | 2024-01-18 | F. Hoffmann-La Roche Ag | Method for producing recombinant aav particles |
| WO2024024337A1 (ja) * | 2022-07-28 | 2024-02-01 | 株式会社ダイセル | 微小有用物質を含む液の精製濃縮装置及びそれを用いた微小有用物質を含む精製濃縮液の製造方法 |
| JP2025530294A (ja) | 2022-09-12 | 2025-09-11 | エフ． ホフマン－ラ ロシュ アーゲー | 完全なａａｖ粒子と空のａａｖ粒子を分離するための方法 |
| EP4385618A1 (en) | 2022-12-16 | 2024-06-19 | Chiral Technologies Europe SAS | Composite material for bioseparations |
| AU2024216670A1 (en) | 2023-02-07 | 2025-07-31 | F. Hoffmann-La Roche Ag | Method for the detection of anti-aav particle antibodies |
| WO2024194280A1 (en) | 2023-03-21 | 2024-09-26 | F. Hoffmann-La Roche Ag | Method for the production of recombinant aav particle preparations |
| EP4694994A1 (en) * | 2023-04-12 | 2026-02-18 | Cytiva BioProcess R&D AB | A chromatography system, use thereof, and a method for separating adeno-associated capsids |
| AU2025218748A1 (en) | 2024-02-09 | 2026-08-06 | F. Hoffmann-La Roche Ag | Method for producing recombinant adeno-associated viral particles |
| WO2025217029A1 (en) * | 2024-04-07 | 2025-10-16 | Spark Therapeutics, Inc. | Compositions & methods for adeno-associated virus capsid variant purification |
| WO2025252480A1 (en) | 2024-06-07 | 2025-12-11 | F. Hoffmann-La Roche Ag | Method for purifying plasmid dna |
| US20260022401A1 (en) | 2024-07-22 | 2026-01-22 | Hoffmann-La Roche Inc. | Novel AAV rep ORFs and Rep polypeptides |
| WO2026037757A1 (en) | 2024-08-13 | 2026-02-19 | F. Hoffmann-La Roche Ag | Modified aav particles |
| WO2026132139A1 (en) | 2024-12-20 | 2026-06-25 | F. Hoffmann-La Roche Ag | Purification process for viral vectors |
| WO2026132012A1 (en) | 2024-12-20 | 2026-06-25 | F. Hoffmann-La Roche Ag | Aav particle processing using affinity chromatography with gradient elution |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2995542A1 (en) * | 1997-09-05 | 1999-03-11 | Genzyme Corporation | Methods for generating high titer helper-free preparations of recombinant aav vectors |
| US6593123B1 (en) * | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
| JP4559429B2 (ja) * | 2003-05-21 | 2010-10-06 | ジェンザイム・コーポレーション | 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法 |
| JP5956331B2 (ja) * | 2009-06-16 | 2016-07-27 | ジェンザイム・コーポレーション | 組換えａａｖベクターの改良された精製方法 |
| EP2529020B1 (en) * | 2010-01-28 | 2018-04-25 | The Children's Hospital of Philadelphia | A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy |
| EP3384015A4 (en) * | 2015-12-01 | 2019-05-29 | Spark Therapeutics, Inc. | SCALABLE PROCESS FOR THE PREPARATION OF A RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR IN A SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR THE CLINICAL APPLICATION |
| US11015174B2 (en) * | 2015-12-11 | 2021-05-25 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAV8 |
| WO2017100674A1 (en) * | 2015-12-11 | 2017-06-15 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aav1 |
| EP3992283A1 (en) * | 2015-12-11 | 2022-05-04 | The Trustees Of The University Of Pennsylvania | Scalable purification method for aavrh10 |
| PH12018502104B1 (en) * | 2016-03-31 | 2024-03-27 | Spark Therapeutics Inc | Column-based fully scalable raav manufacturing process |
-
2018
- 2018-06-29 EP EP18823181.5A patent/EP3658250A4/en active Pending
- 2018-06-29 JP JP2019572175A patent/JP2020526190A/ja active Pending
- 2018-06-29 AU AU2018291023A patent/AU2018291023B2/en active Active
- 2018-06-29 PE PE2025000717A patent/PE20251545A1/es unknown
- 2018-06-29 SG SG11201913157RA patent/SG11201913157RA/en unknown
- 2018-06-29 CA CA3068622A patent/CA3068622A1/en active Pending
- 2018-06-29 CN CN201880053245.7A patent/CN111032176A/zh active Pending
- 2018-06-29 MY MYPI2019007880A patent/MY207534A/en unknown
- 2018-06-29 MX MX2020000216A patent/MX2020000216A/es unknown
- 2018-06-29 PE PE2019002713A patent/PE20200737A1/es unknown
- 2018-06-29 KR KR1020247016903A patent/KR102879640B1/ko active Active
- 2018-06-29 US US16/627,227 patent/US20210079422A1/en active Pending
- 2018-06-29 KR KR1020207002118A patent/KR102669561B1/ko active Active
- 2018-06-29 WO PCT/US2018/040430 patent/WO2019006390A1/en not_active Ceased
-
2019
- 2019-12-29 IL IL271745A patent/IL271745A/en unknown
- 2019-12-30 CL CL2019003915A patent/CL2019003915A1/es unknown
-
2020
- 2020-01-03 PH PH12020500044A patent/PH12020500044A1/en unknown
- 2020-01-08 MX MX2024007103A patent/MX2024007103A/es unknown
- 2020-01-28 CO CONC2020/0000911A patent/CO2020000911A2/es unknown
-
2022
- 2022-11-07 JP JP2022177960A patent/JP2023029832A/ja active Pending
-
2024
- 2024-12-04 JP JP2024211621A patent/JP2025038906A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024007103A (es) | 2024-06-24 |
| PE20251545A1 (es) | 2025-06-05 |
| MY207534A (en) | 2025-03-03 |
| JP2025038906A (ja) | 2025-03-19 |
| RU2020103743A (ru) | 2021-07-30 |
| KR20240093848A (ko) | 2024-06-24 |
| PH12020500044A1 (en) | 2020-09-14 |
| CO2020000911A2 (es) | 2020-06-19 |
| WO2019006390A1 (en) | 2019-01-03 |
| KR102879640B1 (ko) | 2025-10-30 |
| RU2020103743A3 (cg-RX-API-DMAC7.html) | 2021-09-30 |
| CN111032176A (zh) | 2020-04-17 |
| KR102669561B1 (ko) | 2024-05-24 |
| EP3658250A4 (en) | 2021-10-27 |
| AU2018291023B2 (en) | 2023-11-02 |
| PE20200737A1 (es) | 2020-07-23 |
| BR112019028299A2 (pt) | 2020-07-14 |
| US20210079422A1 (en) | 2021-03-18 |
| JP2023029832A (ja) | 2023-03-07 |
| JP2020526190A (ja) | 2020-08-31 |
| IL271745A (en) | 2020-02-27 |
| EP3658250A1 (en) | 2020-06-03 |
| CA3068622A1 (en) | 2019-01-03 |
| AU2018291023A1 (en) | 2020-02-06 |
| SG11201913157RA (en) | 2020-01-30 |
| KR20200040749A (ko) | 2020-04-20 |
| MX2020000216A (es) | 2020-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020000911A2 (es) | Métodos de purificación de columna de vector aav | |
| WO2019241535A3 (en) | Anion exchange chromatography for recombinant aav production | |
| CL2021000517A1 (es) | Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
| CO2018011151A2 (es) | Proceso de producción de raav a base de columnas completamente escalable | |
| EA202090540A1 (ru) | Ген, придающий устойчивость к патогенному грибу | |
| BR112018003127A2 (pt) | purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes | |
| ECSP19005417A (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
| EA202091712A1 (ru) | МОДИФИЦИРОВАННЫЙ КАПСИДНЫЙ БЕЛОК rAAV ДЛЯ ГЕННОЙ ТЕРАПИИ | |
| MX392396B (es) | Anticuerpos especificos para tau hiperfosforilada y metodos de uso de los mismos. | |
| AU2018260998A2 (en) | Modulatory polynucleotides | |
| BR112016029318A2 (pt) | tratamento de mielomas | |
| CR20230026A (es) | Proteínas de fusión gdf15 y usos de estas (divisional 2018-0532) | |
| BR112022012230A2 (pt) | Variantes de progranulina | |
| ECSP10010191A (es) | Anticuerpos antimesotelina y usos de los mismos | |
| PH12022551228A1 (en) | Trem2 antibodies and uses thereof | |
| BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
| BR112019011462A2 (pt) | peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica. | |
| MX2017011189A (es) | Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos. | |
| CU20170112A7 (es) | Variantes de polipeptidos que dividen toxinas de fusarium, aditivo que contiene estas variantes y su uso, así como procedimientos para la división de toxinas de fusarium | |
| PH12019501064A1 (en) | Ras PROTIEIN DEGRADATION INDUCING MOLECULE AND PHARMACEUTICAL COMPOSITION | |
| BR112017011226A2 (pt) | peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica | |
| EA201691834A1 (ru) | Новый способ очистки гонадотропина | |
| MX2021005435A (es) | Transgen abcb11 con codones optimizados para el tratamiento de colestasis intrahepatica familiar progresiva tipo 2 (pfic2). | |
| CY1125117T1 (el) | Ενωσεις μορφολινυλπυριδονης | |
| CL2021000930A1 (es) | Piridazinas novedosas |